SGAM
CHRS icon

Smith Group Asset Management’s Coherus Oncology CHRS Stock Holding History

Smith Group Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-314
Closed -$7K – 472
2015
Q4 		$7K Buy
+314
New +$8.08K ﹤0.01% 425

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Smith Group Asset Management's CHRS Position: Q1 2016 in Review

Smith Group Asset Management sold out of Coherus Oncology (CHRS) in Q1 2016, closing a stake of 314 shares — an estimated $7K sold.

Smith Group Asset Management first reported a position in CHRS in Q4 2015 and held it in 1 quarter. The position peaked at $7K in Q4 2015. 75 funds tracked by Wall St. Rank hold CHRS as of Q1 2016.

  • Smith Group Asset Management reported no remaining Coherus Oncology position as of Q1 2016 after selling out during the quarter.
  • Smith Group Asset Management sold 314 Coherus Oncology shares in Q1 2016, an estimated $7K.
  • Smith Group Asset Management first reported a position in Coherus Oncology in Q4 2015 and held it in 1 quarter.
  • Smith Group Asset Management's Coherus Oncology position peaked at $7K in Q4 2015.
  • 75 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2016.

Based on Smith Group Asset Management's 13F filing for Q1 2016, filed 3 May 2016.